<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38541221</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">495</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60030495</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: the principal purpose of this literature review is to cluster adults with hematological malignancies after treatment or on maintenance with obinutuzumab who experienced disseminated EV infection to understand clinical characteristics and outcome of this rare condition in these patients. We report the first clinical case of a male affected by follicular lymphoma treated with immune-chemotherapy including obinutuzumab who was affected by disseminated EV infection with cardiovascular involvement. <i>Materials and Methods</i>: this narrative review summarizes all the research about disseminated EV infection in immunosuppressed adult patients treated with obinutuzumab from January 2000 to January 2024 using the Scale for the Assessment of Narrative Review Articles (SANRA) flow-chart. We performed a descriptive statistic using the standard statistical measures for quantitative data. <i>Results</i>: we included six studies, five case reports, and one case report with literature analysis. We collected a total of seven patients, all female, with disseminated EV infection. The most common signs and clinical presentations of EV infection were fever and encephalitis symptoms (N = 6, 85.7%), followed by hepatitis/acute liver failure (N = 5, 71.4%). <i>Conclusions</i>: onco-hematological patients who receive immune-chemotherapy with a combination of treatments which depress adaptative immunity, which includes the antiCD20 obinutuzumab, could be at higher risk of disseminated EV infection, including CNS and cardiac involvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lupia</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3865-9519</Identifier><AffiliationInfo><Affiliation>Unit of Infectious Diseases, AOU City of Health and Sciences, 10100 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcione</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, AOU City of Health and Sciences, 10100 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staffilano</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0006-0369-8426</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosio</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtoni</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8101-4196</Identifier><AffiliationInfo><Affiliation>Microbiology and Virology Unit, AOU City of Health and Sciences, 10100 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busca</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5361-5613</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Stem Cell Transplant Center, Città Della Salute e Della Scienza Hospital, 10100 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Francesco Giuseppe</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0001-8338-0130</Identifier><AffiliationInfo><Affiliation>Unit of Infectious Diseases, AOU City of Health and Sciences, 10100 Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PE00000007, INF-ACT</GrantID><Agency>EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>O43472U9X8</RegistryNumber><NameOfSubstance UI="C543332">obinutuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008224" MajorTopicYN="Y">Lymphoma, Follicular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">encephalitis</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">hematological malignancy</Keyword><Keyword MajorTopicYN="N">lymphoma</Keyword><Keyword MajorTopicYN="N">obinutuzumab</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38541221</ArticleId><ArticleId IdType="pmc">PMC10972032</ArticleId><ArticleId IdType="doi">10.3390/medicina60030495</ArticleId><ArticleId IdType="pii">medicina60030495</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Committee on the Enteroviruses. National Foundation for Infantile Paralysis The Enteroviruses. Am. J. Public Health Nations Health. 1957;47:1556–1566. doi: 10.2105/AJPH.47.12.1556.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.47.12.1556</ArticleId><ArticleId IdType="pmc">PMC1551439</ArticleId><ArticleId IdType="pubmed">13487867</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari A., Motta M., Singh S., Kasniya G., Mane S.S., Cartaya S., Rahman M.M., Dudeja P. Enteroviral Infections in Infants. Newborn. 2022;1:297–305. doi: 10.5005/jp-journals-11002-0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-11002-0036</ArticleId><ArticleId IdType="pmc">PMC9599990</ArticleId><ArticleId IdType="pubmed">36304567</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubelt B., Lipton H.L. Handbook of Clinical Neurology. Volume 123. Elsevier BV; Amsterdam, The Netherlands: 2014. Enterovirus/Picornavirus infections; pp. 379–416.</Citation><ArticleIdList><ArticleId IdType="pubmed">25015496</ArticleId></ArticleIdList></Reference><Reference><Citation>Misbah S.A., Spickett G.P., Ryba P.C.J., Hockaday J.M., Kroll J.S., Sherwood C., Kurtz J.B., Moxon E.R., Chapel H.M. Chronic enteroviral meningoencephalitis in agammaglobulinemia: Case report and literature review. J. Clin. Immunol. 1992;12:266–270. doi: 10.1007/BF00918150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00918150</ArticleId><ArticleId IdType="pubmed">1512300</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone A., Roulland S., Gloghini A., Younes A., von Keudell G., López-Guillermo A., Fitzgibbon J. Follicular lymphoma. Nat. Rev. Dis. Prim. 2019;5:83. doi: 10.1038/s41572-019-0132-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0132-x</ArticleId><ArticleId IdType="pubmed">31831752</ArticleId></ArticleIdList></Reference><Reference><Citation>Baethge C., Goldbeck-Wood S., Mertens S. SANRA—A scale for the quality assessment of narrative review articles. Res. Integr. Peer Rev. 2019;26:5. doi: 10.1186/s41073-019-0064-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41073-019-0064-8</ArticleId><ArticleId IdType="pmc">PMC6434870</ArticleId><ArticleId IdType="pubmed">30962953</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. In: Li W., editor. Leukemia. Exon Publications; Brisbane, Australia: 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">36395314</ArticleId></ArticleIdList></Reference><Reference><Citation>Heger J., Eichenauer D.A., Kasper P., Böll B., Shimabukuro-Vornhagen A., Kochanek M. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy. Eur. J. Haematol. 2019;103:268–271. doi: 10.1111/ejh.13278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13278</ArticleId><ArticleId IdType="pubmed">31211882</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendle C., Gilbertson M., Korman T.M., Golder V., Morand E., Opat S. Disseminated Enteroviral Infection Associated with Obinutuzumab. Emerg. Infect. Dis. 2015;21:1661–1663. doi: 10.3201/eid2109.150104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2109.150104</ArticleId><ArticleId IdType="pmc">PMC4550142</ArticleId><ArticleId IdType="pubmed">26291712</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyckmans T., Wollants E., Janssens A., Schoemans H., Lagrou K., Wauters J., Maertens J. Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013. Emerg. Infect. Dis. 2014;20:913–915. doi: 10.3201/eid2005.131766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2005.131766</ArticleId><ArticleId IdType="pmc">PMC4012818</ArticleId><ArticleId IdType="pubmed">24751368</ArticleId></ArticleIdList></Reference><Reference><Citation>Blau B.J., Bass A.R. Chronic Enterovirus Infection Manifesting as Diffuse Myalgias and Arthralgias in a 67-Year-Old Woman Receiving Obinutuzumab. Grand Rounds from HSS: Management of Complex Cases, 2023, Volume 12, Issue 3.  [(accessed on 10 February 2024)].  Available online:  https://www.hss.edu/conditions_complexcase-chronic-enterovirus-infection.asp.</Citation></Reference><Reference><Citation>Wagner J.N., Leibetseder A., Troescher A., Panholzer J., von Oertzen T.J. Characteristics and therapy of enteroviral encephalitis: Case report and systematic literature review. Int. J. Infect. Dis. 2021;113:93–102. doi: 10.1016/j.ijid.2021.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.002</ArticleId><ArticleId IdType="pubmed">34628025</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil T., Hannah R., Hui C., Qiao M. Disseminated enterovirus infection in a patient treated with obinutuzumab. J. Med. Virol. 2022;94:439–441. doi: 10.1002/jmv.27370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27370</ArticleId><ArticleId IdType="pubmed">34590740</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 10 February 2024)].  Available online:  https://fda-approves-gazyva-chronic-lymphocytic-leukemia-3955.html.</Citation></Reference><Reference><Citation> [(accessed on 10 February 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1054.</Citation></Reference><Reference><Citation>Marcus R., Davies A., Ando K., Klapper W., Opat S., Owen C., Phillips E., Sangha R., Schlag R., Seymour J.F., et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N. Engl. J. Med. 2017;377:1331–1344. doi: 10.1056/NEJMoa1614598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1614598</ArticleId><ArticleId IdType="pubmed">28976863</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N., Lamonte-Fowlkes A., Oberst S., Pallansch M.A., Centers for Disease Control and Prevention . Enterovirus Surveillance–United States, 1970–2005. Morbidity and Mortality Weekly Report. Surveillance Summaries. Volume 55. Centers for Disease Control and Prevention; Washington, DC, USA: 2002. pp. 1–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971890</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikonov O.S., Chernykh E.S., Garber M.B., Nikonova E.Y. Enteroviruses: Classification, diseases they cause, and approaches to development of antiviral drugs. Biochemistry. 2017;82:1615–1631. doi: 10.1134/s0006297917130041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/s0006297917130041</ArticleId><ArticleId IdType="pmc">PMC7087576</ArticleId><ArticleId IdType="pubmed">29523062</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisariu S., Vaxman I., Gatt M., Elias S., Avni B., Arad A., Pasvolsky O., Raanani P., Paltiel O. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: A case series and review of the literature. Hematol. Oncol. 2017;35:591–598. doi: 10.1002/hon.2365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2365</ArticleId><ArticleId IdType="pubmed">27734521</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn J.J. Enteroviruses and Parechoviruses. Microbiol. Spectr. 2016;4:273–296. doi: 10.1128/microbiolspec.dmih2-0006-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.dmih2-0006-2015</ArticleId><ArticleId IdType="pubmed">27337462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P.G.E. An overview of viral infections of the nervous system in the immunosuppressed. J. Neurol. 2021;268:3026–3030. doi: 10.1007/s00415-020-10265-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10265-z</ArticleId><ArticleId IdType="pmc">PMC7552955</ArticleId><ArticleId IdType="pubmed">33048220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafter-Gvili A., Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk. Lymphoma. 2016;57:512–519. doi: 10.3109/10428194.2015.1110748.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2015.1110748</ArticleId><ArticleId IdType="pubmed">26696321</ArticleId></ArticleIdList></Reference><Reference><Citation>Amitai I., Gafter-Gvili A., Shargian-Alon L., Raanani P., Gurion R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol. Oncol. 2021;39:215–221. doi: 10.1002/hon.2828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2828</ArticleId><ArticleId IdType="pubmed">33252145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kainulainen L., Vuorinen T., Rantakokko-Jalava K., Österback R., Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J. Allergy Clin. Immunol. 2010;126:120–126. doi: 10.1016/j.jaci.2010.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2010.04.016</ArticleId><ArticleId IdType="pmc">PMC7112312</ArticleId><ArticleId IdType="pubmed">20541246</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liu M., Yan Y., Wang Z., Dai Q., Yang X., Guo X., Li W., Chen X., Cao R., et al. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses. 2022;14:1142. doi: 10.3390/v14061142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061142</ArticleId><ArticleId IdType="pmc">PMC9227765</ArticleId><ArticleId IdType="pubmed">35746614</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein S., Thakkar R., Fong K.T., Ng J., Bearden D.R., Mishra N., Thakur K.T., Riley C.S. Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis. J. Neurovirol. 2022;28:329–334. doi: 10.1007/s13365-021-01038-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-01038-z</ArticleId><ArticleId IdType="pubmed">34981437</ArticleId></ArticleIdList></Reference><Reference><Citation>Amdani S.M., Kim H.S., Orvedahl A., John A.O., Said A., Simpson K. Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir. BMJ Case Rep. 2018;2018:bcr2017224133. doi: 10.1136/bcr-2017-224133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2017-224133</ArticleId><ArticleId IdType="pmc">PMC5965763</ArticleId><ArticleId IdType="pubmed">29776940</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir P., Tilzey A., English T., Nicholson F., Signy M., Banatvala J. Chronic relapsing pericarditis and dilated cardiomyopathy: Serological evidence of persistent enterovirus infection. Lancet. 1989;333:804–807. doi: 10.1016/S0140-6736(89)92270-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)92270-8</ArticleId><ArticleId IdType="pubmed">2564902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>